Hinova Pharmaceuticals Hits Day Low of CNY 33.51 Amid Price Pressure

Hinova Pharmaceuticals, Inc. experienced a significant decline in its stock performance today, dropping by 7.5% and reaching an intraday low of CNY 33.51. This downturn is part of a broader trend, as the company has seen a 14.93% decrease over the past week and a substantial 23.22% drop in the last month. In stark contrast, the China Shanghai Composite index has only fallen by 1.7% today and 2.43% over the past week. The small-cap pharmaceutical company has faced ongoing challenges, reflected in its year-to-date performance, which stands at a loss of 29.06%. Over the past year, Hinova's stock has decreased by 31.15%, while the broader market has shown a positive return of 16.95%. Financial metrics indicate that Hinova is grappling with poor management efficiency, highlighted by a return on capital employed (ROCE) of 0% and negative net worth. The company has reported losses, with a net profit of CNY -70.84 million in its latest half-year results. As it navigates these financial hurdles, Hinova remains a part of the Reliable Performers category on MarketsMOJO since September 2025.